Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research (5:36).
Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.
Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.
Cancer 2018; doi:10.1002/cncr.31760 JAMA Network Open 2018; 1: e183023
Progression-free survival should not be used as a surrogate marker for health-related quality of life as there is no correlation between them, results of a systematic review and quantitative analysis of randomized clinical trials show.
JAMA Intern Med 2018; doi:10.1001/jamainternmed.2018.4710
Patients who undergo video-assisted thoracoscopic surgery for stage I non-small-cell lung cancer are less likely to become long-term opioid users than their counterparts undergoing the conventional open procedure, findings suggest.
Men with high-risk nonmetastatic castration-resistant prostate cancer do not report a deterioration in health-related quality of life when androgen deprivation therapy is supplemented with apalutamide, indicate SPARTAN trial results.
The PARP inhibitor talazoparib extends progression-free survival and improves quality of life compared with standard chemotherapy, show findings from the phase III EMBRACA study of women with advanced breast cancer and a germline BRCA1/2 mutation.
N Engl J Med 2018; 379: 753–763 Ann Oncol 2018; doi:10.1093/annonc/mdy257
The birth rate for women who are relapse-free after treatment for Hodgkin lymphoma has risen in recent years, becoming comparable with that of the general population regardless of disease stage or treatment.
Trial results suggest that cognitive behavioral therapy for insomnia is more effective than acupuncture for reducing the severity of insomnia symptoms in cancer survivors, although both approaches offer benefits.
Patient-reported outcomes and quality of life are better with second-line osimertinib than chemotherapy in patients with T790M-positive advanced non-small-cell lung cancer, shows an analysis of the AURA 3 trial.
Women with early breast cancer have similar quality of life at 5 years whether they are treated with accelerated partial breast irradiation using multicatheter brachytherapy or whole-breast irradiation, GEC-ESTRO data show.
In an aging population with rising obesity levels, comorbidities and worse overall prognoses for breast cancer patients are a growing concern. Damien Hansra (Cancer Treatment Centers of America, GA, USA) calls for more education and preparation to combat this concerning public health threat.
Health-related quality of life analyses from the KEYNOTE-045 phase III study show that pembrolizumab prolongs time to deterioration in previously treated patients with advanced urothelial cancer compared with chemotherapy.
In men with metastatic hormone-sensitive prostate cancer, the addition of docetaxel to androgen deprivation therapy leads to an initial dip in quality of life, with a subsequent benefit over time, show CHAARTED results published in the Journal of Clinical Oncology.
Here we provide top-line summaries of results from three phase III breast cancer trials, evaluating nab-paclitaxel and a trastuzumab biosimilar in the nonmetastatic HER2-negative and -positive settings, respectively, and quality of life with the addition of palbociclib in the advanced or metastatic setting.